Abstract
The prognostic role of Extracellular matrix metalloproteinase inducer (EMMPRIN/ CD147) in gastrointestinal cancer remains controversial. We systematically reviewed the evidence of assessment of CD147 expression in gastrointestinal cancer to help clarify this issue. Pubmed, Embase, Cochrane Library and Web of Science databases were searched to identify eligible studies to evaluate the association of CD147 expression and disease-free and overall survival of gastrointestinal cancer. Hazard ratios (HRs) were pooled to estimate the effect. CD147 overexpression was significantly correlated with poor disease-free survival (HR 2.38, 95% CI 1.43–3.97) and overall survival (HR 1.64, 95% CI 1.25–2.14) of cancer patients. Furthermore, CD147 overexpression was significantly association with TNM stage (TIII/TIV vs TI/TII: OR 3.60, 95% CI 1.85–7.01), the depth of invasion (T3/T4 vs T1/T2: OR 2.04, 95% CI 1.25–3.33), lymph node metastasis (positive vs negative: 2.35, 95% CI 1.14–4.86), distant metastasis (positive vs negative: OR 4.78, 95% CI 1.43–16.00). Our analyses demonstrate that CD147 was effectively predictive of worse prognosis in gastrointestinal cancer. Moreover, Identifying CD147 may help identify new drug targets for cancer therapy.
Highlights
Gastrointestinal cancers are the main malignant tumors in both men and women worldwide [1, 2]
CD147 plays a key role in degradation of the extracellular matrix (ECM) through matrix metalloproteinase (MMPs) induction [27,28,29], regulates vascular endothelial growth factor (VEGF) expression [30], stimulates proliferation, migration, and cell survival independently of MMPs [31], and leads to multidrug resistance to some chemotherapeutic drugs [32]
This is the first meta-analysis to assess the association between CD147 expression and disease-free and overall survival of gastrointestinal cancer patients
Summary
Gastrointestinal cancers are the main malignant tumors in both men and women worldwide [1, 2]. Progression has been made in its diagnosis and treatment, some gastrointestinal cancers are still incurable. This is largely because most patients are at an advanced stage at the time of diagnosis, so have a correspondingly poor prognosis. Disease prognosis correlates directly with the incidence of carcinoma relapse, which is mainly caused by early metastasis. The prediction of tumor relapse and the prevention of early metastasis is a promising therapy for gastrointestinal cancer. It is very important to confirm prognostic markers for gastrointestinal cancer which can help identify better preventive methods for gastrointestinal cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
